X

Trial Profile

Lonsurf - RII Lonsurf (TAS-102) with or without bevacizumab in patients with chemo-refractory metastatic colorectal cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tipiracil/trifluridine (Primary) ; Bevacizumab
Indications Adenocarcinoma; Colorectal cancer
Focus Therapeutic Use

Most Recent Events

01 Jul 2023 Results of updated PFS and OS, presented at the 25th World Congress on Gastrointestinal Cancer
04 Jul 2020 Results (n=93; as of 1 Feb 2020) of updated survival analysis presented at the 22nd World Congress on Gastrointestinal Cancer
27 Jan 2020 Results published in the Lancet Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com